Arbutus Biopharma (ABUS) Receivables - Net (2010 - 2026)

Arbutus Biopharma (ABUS) has reported Receivables - Net for 17 consecutive years, with $178.7 million the latest figure, recorded in Q1 2026.

• Quarterly Receivables - Net rose 15021.91% year-over-year to $178.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $178.7 million (up 15021.91% YoY) and the FY2025 annual result came in at $1.4 million, down 39.93% from the prior year.
• Receivables - Net rose to $178.7 million in Q1 2026 per ABUS's latest filing, from $1.4 million in the prior quarter.
• Over the last five years, Receivables - Net for ABUS reached as high as $178.7 million in Q1 2026 and fell as low as $905000.0 in Q3 2025.
• A 5-year average of $12.2 million and a median of $1.8 million in 2023 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2025 — Receivables - Net slumped 44.74% — and 2026, when it jumped 15021.91%.
• Year by year, Receivables - Net stood at $1.4 million in 2022, then surged by 31.36% to $1.8 million in 2023, then jumped by 35.64% to $2.4 million in 2024, then plunged by 39.93% to $1.4 million in 2025, then soared by 12252.52% to $178.7 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $178.7 million, $1.4 million, and $905000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.